FRESCO-2: Fruquintinib in Patients with Refractory Metastatic CRC


Arvind N. Dasari, MD, MS, provides a comprehensive overview of the FRESCO-2 trial investigating fruquintinib in patients with refractory metastatic colorectal cancer.

Related Videos
Video 18 - "Reflecting on Differentiated Thyroid Cancer: Final Insights"
Video 17 - "Phase 2 ATLEP Trial Results"
Michael Iglesia, MD, PhD
Video  10 -"Real-World Evidence on Second-Line Therapy Selection and Outcomes"
Video  9 - "Additional Second-Line Treatments for HCC"
Jin Qian, PhD
Video 16 - "Neoadjuvant Approach in RAI-R-DTC"
Video 15 - "Addressing Unmet Needs and Challenges in RAI-R-DTC Treatment"
A panel of 4 experts on colorectal cancer
Video 8 - "The Evolving Landscape of Second-Line Therapies in HCC Management"